報價延遲最少15分鐘:2026/03/02 07:20 EST
盤前時段
|
||||
|
-- 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
91.68
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.23/-6.81
|
|
企業價值
247.14M
|
| 資產負債 |
|
每股賬面淨值
9.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
11.54M
|
|
每股收益
0.45
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includesSGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease andother rare keratosis-related indications such as PC, PPK and Olmsted. |
